Seres Therapeutics Investor Presentation May 2024

Seres Therapeutics presents its microbiome therapeutics strategy, featuring VOWST, the first FDA-approved orally administered microbiome therapeutic. The deck covers the company's clinical pipeline including the SER-155 Phase 1b study and outlines strategic priorities with financial discipline.